Annals of Surgical Oncology, Vol 7, Issue 4 268-275, Copyright © 2000 by Society of Surgical Oncology

ARTICLES

Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage

T. C. Stam, A. J. Swaak, M. R. de Vries, T. L. ten Hagen and A. M. Eggermont
Department of Surgical Oncology, University Hospital Rotterdam-Dr. Daniel den Hoed Cancer Center, The Netherlands.

BACKGROUND: Since the introduction of high-dose tumor necrosis factor-alpha (TNFalpha) in the setting of isolated limb perfusion (ILP) in the clinic, prevention of leakage to the body of the patient is monitored with great precision for fear of TNF-mediated toxicity. That we observed remarkably little toxicity in patients with and without leakage prompted us to determine patterns of cytokines and acute phase proteins in patients with high leakage and in patients without any leakage. METHODS: TNFalpha, interleukin (IL)-6, IL-8, C-reactive protein, and secretory (s)-phospholipase A2 were measured at several time points during and after (until 7 days) ILP in 10 patients with a leakage to the systemic circulation varying in percentage from 12% to 65%. As a control, the same measurements, both in peripheral blood and in perfusate, were performed in nine patients without systemic leakage. RESULTS: In patients with systemic leakage, levels of TNFalpha increased during ILP, reaching values to 277 ng/ml. IL-6 and IL-8 peaked 3 hours after ILP with values significantly higher compared with patients without systemic leakage. C-reactive protein and s-phospholipase A2 peaked at day 1 in both patient groups, s-phospholipase A2 with significant higher levels and C-reactive protein, in contrast, with lower levels in the leakage patients. CONCLUSIONS: High leakage of TNFalpha to the systemic circulation, caused by a complicated ILP, led to 10-fold to more than 100-fold increased levels of TNFalpha, IL-6, and IL-8 in comparison with patients without leakage. The increase of the acute phase proteins was limited. Even when high leakage occurs, this procedure should not lead to fatal complications. The most prominent clinical toxicity was hypotension (grade III in four patients), which was easily corrected. No pulmonary or renal toxicity was observed in any patient. It is our experience that, even in the rare event of significant leakage during a TNFa-based ILP, postoperative toxicity is usually mild and can be easily managed by the use of fluid and, in some cases, vasopressors.

This article has been cited by other articles:

				D. J. Grunhagen, B. van Etten, F. Brunstein, W. J. Graveland, A. N. van Geel, J. H. W. de Wilt, and A. M. M. Eggermont Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor {alpha} and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure Ann. Surg. Oncol., August 1, 2005; 12(8): 609 - 615. [Abstract] [Full Text] [PDF]

				B. van Etten, A. N. van Geel, J. H. W. de Wilt, and A. M. M. Eggermont Fifty Tumor Necrosis Factor-Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors Ann. Surg. Oncol., January 1, 2003; 10(1): 32 - 37. [Abstract] [Full Text] [PDF]

				E.M. Noorda, B.C. Vrouenraets, O.E. Nieweg, A.N. van Geel, A.M. M. Eggermont, and B.B. R. Kroon Safety and Efficacy of Isolated Limb Perfusion in Elderly Melanoma Patients Ann. Surg. Oncol., December 1, 2002; 9(10): 968 - 974. [Abstract] [Full Text] [PDF]

				U. Stein, K. Jurchott, M. Schlafke, and P. Hohenberger Expression of Multidrug Resistance Genes MVP, MDR1, and MRP1 Determined Sequentially Before, During, and After Hyperthermic Isolated Limb Perfusion of Soft Tissue Sarcoma and Melanoma Patients J. Clin. Oncol., August 1, 2002; 20(15): 3282 - 3292. [Abstract] [Full Text] [PDF]

				R. J. van Ginkel, P. C. Limburg, D. A. Piers, H. S. Koops, and H. J. Hoekstra Value of Continuous Leakage Monitoring With Radioactive Iodine-131-Labeled Human Serum Albumin During Hyperthermic Isolated Limb Perfusion With Tumor Necrosis Factor-{alpha} and Melphalan Ann. Surg. Oncol., May 1, 2002; 9(4): 355 - 363. [Abstract] [Full Text] [PDF]

				D. Daryanani, R. Komdeur, J. Ter Veen, P.H. Nijhuis, D.A. Piers, and H.J. Hoekstra Continuous Leakage Measurement During Hyperthermic Isolated Limb Perfusion Ann. Surg. Oncol., August 1, 2001; 8(7): 566 - 572. [Abstract] [Full Text] [PDF]